Tipapkinogene sovacivec

Drug Profile

Tipapkinogene sovacivec

Alternative Names: MVA-HPV-IL2 vaccine; R-3484; RG 3484; RO5217790; TG 4001

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transgene
  • Developer European Organisation for Research and Treatment of Cancer; Merck & Co; Roche; Transgene
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Oropharyngeal cancer
  • Discontinued Cervical cancer; Cervical intraepithelial neoplasia; Head and neck cancer

Most Recent Events

  • 19 Sep 2017 Phase-I/II clinical trials in Oropharyngeal cancer (Combination therapy, Second-line therapy or greater) in France (SC) (NCT03260023)
  • 20 Mar 2017 Transgene, in collaboration with Merck and Pfizer, plans a phase II trial for HPV-positive Head and neck cancer in France in the second half of 2017
  • 11 Oct 2016 Transgene, Merck and Pfizer agree to co-develop TG4001 in France for Head and neck cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top